Tumor cell-derived C3a is an important cancer-promoting factor in TME and can enhance immunosuppression to promote tumor cell growth via the C3a-C3aR signaling pathway, providing a potential target for immune checkpoint block (ICB) therapy (23). This evidence concerns the gene C3AR1 and cancer.